Teva Pharma (TEVA) PT Raised to $11 at RBC Capital
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.46 -2.75%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 17 | New: 22
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky raised the price target on Teva Pharma (NYSE: TEVA) to $11.00 (from $8.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Teva in talks with Trump administration on Medicaid drug pricing
- CLSA Upgrades Taiyo Yuden Co Ltd (6976:JP) (TYOYY) to High-Conviction Outperform (1)
- Oracle Corp Japan (4716:JP) (OCLCF) PT Lowered to JPY13,000 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
